Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- N-(1-oxohexadecyl)-L-serylglycyl-L-arginyl-L-arginyl-L-tyrosylglycyl-L-histidyl-L-alanyl-L-leucyl-L-argininamide, trifluoroacetate salt
- Correlated keywords
- 1021346-05-3 TFA Pepducin P 4pal10 P4pal-10 PAR FPR FFAR GPR-43 AYPGKFNH2 SFLLRNNH2 U46619 TNF? Cmp-58 SGRRYGHALRNH2
- Product Overview:
P4pal10 is a pepducin antagonist of proteinase-activated receptor 4 (PAR4) and formyl peptide receptor 2 (FPR2), as well as an agonist of free fatty acid receptor 2 (FFAR2/GPR43).{21094,66196} It is composed of a peptide that corresponds to the third intracellular loop of human PAR4 that is conjugated to palmitic acid (Item No. 10006627).{21094} P4pal10 selectively inhibits the aggregation of isolated human platelets induced by the PAR4 peptide agonist AYPGKF-NH2 (Item No. 24258; IC50 = 0.5-1 µM) over the PAR1 peptide agonist SFLLRN-NH2 (Item No. 36881), the TP receptor agonist U-46619 (Item No. 16450), the platelet glycoprotein Ib (GPIb), GPIX, and GPV agonist ristocetin, ADP (Item No. 21121), or collagen at 5 µM. It inhibits increases in intracellular calcium induced by the FPR1 and FPR2 agonist WKYMVm but not by the FPR1 agonist fMLF in isolated human neutrophils and induces superoxide production in TNF-? primed isolated human neutrophils stimulated with the FFAR2 allosteric modulator Cmp58.{66196} P4pal10 (1, 3, or 10 µg/kg) reduces myocardial infarct size in a rat model of coronary artery ligation-induced ischemia-reperfusion injury.{67051} It increases the paw withdrawal threshold in rat models of osteoarthritis induced by monoiodoacetate injection into the knee joint or medial meniscal transection.{66197}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.